DA-LIANG OULiao, Zi-XianZi-XianLiaoKempson, Ivan MIvan MKempsonLi, LinLinLiPAN-CHYR YANGTseng, S-JaS-JaTseng2024-01-092024-01-092024-01-0210217770https://scholars.lib.ntu.edu.tw/handle/123456789/638307As of 2020, hepatocellular carcinoma (HCC), a form of liver cancer, stood as the third most prominent contributor to global cancer-related mortality. Combining immune checkpoint inhibitors (ICI) with other therapies has shown promising results for treating unresectable HCC, offering new opportunities. Recombinant adeno-associated viral type 2 (AAV2) virotherapy has been approved for clinical use but it efficacy is stifled through systemic administration. On the other hand, iron oxide nanoparticles (ION) can be cleared via the liver and enhance macrophage polarization, promoting infiltration of CD8+ T cells and creating a more favorable tumor microenvironment for immunotherapy.enAdeno-associated virus; Immune-promoting effect; Iron oxide nanoparticles; Macrophage; Orthotopic hepatocellular carcinoma; Photodynamic virotherapy[SDGs]SDG3journal article10.1186/s12929-023-00989-1381638942-s2.0-85181227761https://api.elsevier.com/content/abstract/scopus_id/85181227761